Navigation Links
Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
Date:6/13/2013

ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York City. This event will be accessible via a live webcast through the following internet link, https://viavid.webcasts.com/starthere.jsp?ei=1018556

Keynote speaker, Rhonda R. Voskuhl, M.D., will join Synthetic Biologics' executive management remotely for the presentations. Dr. Voskuhl is Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA School of Medicine, and the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS). An overview of MS and the current market, as well as the history of estriol and its role in the treatment of MS will be discussed.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
2. Synthetic Biologics Reports First Quarter 2013 Financial Results
3. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
4. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
5. Synthetic Biologics Reports Year End 2012 Financial Results
6. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
7. Synthetic Biologics to Present at the 25th Annual ROTH Conference
8. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
9. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
10. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
11. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 Ascendis Pharma ... innovative TransCon technology to address significant unmet medical needs ... host a conference call and webcast on Monday, April ... Endocrine Society in Orlando, Florida , ... pipeline candidates (TransCon Growth Hormone, TransCon PTH and TransCon ...
(Date:3/23/2017)... DIEGO , March 23, 2017  A ... fast and accurate identification of individuals who carry ... risk for a rare yet potentially deadly side ... and bipolar disorder.  The gene HLA-B*15:02 ... reactions such as Stevens-Johnson syndrome and toxic epidermal ...
(Date:3/23/2017)... Prima BioMed has presented encouraging ... IMP321 in combination with Keytruda, with one of the ... a complete response. Recruitment in the second cohort is ... fully recruited by Q317. Preliminary efficacy data from the ... are expected mid-year (recruitment in the 226-patient Phase IIb ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... In just two ... Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so ... nearly 2,000 consumers (and counting) already backing the campaign. , “We are ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... ) announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center ... in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by ...
(Date:3/24/2017)... ... 24, 2017 , ... “Finding Christ Through Social Media: Year ... chronicling the writer’s path toward true communion with God. “Finding Christ Through Social ... the creation of published author Lea Michelle Johnson, a follower of Christ, wife ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The ... about real people of God in congregations across the United States. “The ... minister ordained in 1964 who has served congregations in seven states throughout his ...
Breaking Medicine News(10 mins):